Prospective Phenotyping of Autonomous Aldosterone Secretion

Status Active, not recruiting

Clinical Trial Summary

This prospective cohort study will investigate the physiology and progression of autonomous aldosterone secretion.

Clinical Trial Description

Primary aldosteronism is a disorder wherein aldosterone is secreted by the adrenal gland(s) independent of its physiologic regulators and cannot be appropriately suppressed with sodium/volume loading. Primary aldosteronism is a common cause of hypertension and has a relatively high prevalence. This is important since the excessive mineralocorticoid receptor activation in primary aldosteronism contributes to adverse cardiovascular and renal outcomes and death. For these reasons, it is critical that autonomous aldosteronism be detected early in its course since appropriate treatment interventions may prevent cardiovascular disease. In addition to severe and overt primary aldosteronism in hypertension, human studies have shown that milder forms of primary aldosteronism can exist even among normotensive individuals. Detailed physiologic studies have shown that normotensive individuals with a phenotype of autonomous aldosterone secretion have greater cardiometabolic risk factors, impaired renal-vascular function, and a higher risk for developing incident hypertension. Further, older age is associated with greater autonomous aldosterone secretion, suggesting that autonomous aldosterone secretion may progress over time. A better understanding of the prevalence and progression of this type of "subclinical" autonomous aldosterone secretion may inform our understanding of the pathogenesis of hypertension and cardiometabolic diseases. This protocol is designed to be a prospective longitudinal study that will carefully characterize the degree of autonomous aldosterone secretion among high-risk normotensive individuals and follow them longitudinally with repeated phenotyping study visits to assess the progression and severity of autonomous aldosterone secretion over time and its relevance to cardiovascular health. Phenotyping visits will include measurements of the renin-angiotensin-aldosterone system under controlled posture and variable sodium intakes and repeated assessments of blood pressure. This prospective cohort study will provide insights into normal and abnormal aldosterone physiology over time and how it may contribute to time- or age-dependent hypertension and cardiometabolic risk. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03484130
Study type	Observational
Source	Brigham and Women's Hospital
Contact
Status	Active, not recruiting
Phase
Start date	June 15, 2018
Completion date	April 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03255187` - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution	N/A
Recruiting	`NCT05997303` - Continuous Norepinephrine Administration and Blood Pressure Stability During Anesthetic Induction	N/A
Recruiting	`NCT04575194` - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy	Phase 4
Completed	`NCT03918486` - Caretaker vs. Routine Blood Pressure Sphygmomanometer
Completed	`NCT03410342` - The Effects of Types of Fruits and Vegetables on Vascular Function	N/A
Active, not recruiting	`NCT05062161` - Sleep Duration and Blood Pressure During Sleep	N/A
Not yet recruiting	`NCT04087070` - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Completed	`NCT03294928` - Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers	N/A
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Completed	`NCT03997461` - Comparison of Arterial Tonometry Sensor With Standard Oscillometric Blood Pressure Monitoring Device	N/A
Completed	`NCT03290716` - Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China	N/A
Recruiting	`NCT05196048` - Blood Pressure Sensor of Watch-type Device With ECG Technology
Terminated	`NCT03325933` - Resistance Training and Cardiometabolic Health	N/A
Completed	`NCT02924454` - Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.	Phase 4
Completed	`NCT02451059` - Reducing Socioeconomic Disparities in Health at Pediatric Visits	N/A
Active, not recruiting	`NCT02670967` - Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials	N/A
Completed	`NCT02271633` - Nitrate Supplementation; Source	Phase 4
Completed	`NCT02239744` - Intervention Study on the Health Impact of Air Filters in Chinese Adults	N/A
Terminated	`NCT01633814` - Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women	N/A
Completed	`NCT01277614` - Therapeutic Lifestyle Modifications to Reduce Burden of Chronic Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.